Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-EN Version v3-EN
Language English English
Date Updated 2021-02-10 2021-01-15
Drug Identification Number 02139529 02139529
Brand name SODIUM ACETATE INJECTION, USP SODIUM ACETATE INJECTION, USP
Common or Proper name Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients SODIUM ACETATE SODIUM ACETATE
Strength(s) 328MG 328MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 100 mL 100 mL
ATC code B05XA B05XA
ATC description I.V. SOLUTION ADDITIVES I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2021-01-06 2021-01-06
Actual start date
Estimated end date Unknown Unknown
Actual end date 2021-02-09
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada Ltd. is pleased to advise that our Sodium Acetate Injection will be removed off allocation effective today, Tuesday, February 9, 2021. The product will be available to all customers without restrictions. Allocation changing to weekly Effective January 6, 2021. Remains on 75% allocation
Health Canada comments